Solon Ventures

Fever Labs, Inc. operates a mobile application that serves as a social discovery tool, offering users a curated list of local events in various cities, including New York, Madrid, and London. The app provides comprehensive information on a wide range of experiences, such as concerts, exhibitions, parties, comedy shows, and attractions, along with ticket booking options. With a focus on enhancing the Experience Economy, Fever connects over 40 million users monthly with the best local activities, while also empowering event organizers to create original content. Founded in 2011 and initially known as Kzemos, Inc., Fever has established itself as a leader in the digitization of experiences, helping individuals discover and enjoy diverse cultural and entertainment offerings.

Prosonix Ltd. operates as a specialty pharmaceutical company, which develops and markets a portfolio of inhaled respiratory medicines to treat asthma and chronic obstructive pulmonary diseases. It develops generic mono and combination therapies based on inhaled corticosteroids (ICS), long-acting beta agonists (LABA), and long-acting muscarinic antagonists (LAMA); and dual and triple combination therapies for respiratory diseases based on its multiple-component particle technology. The company was founded in 2006 and is based in Oxford, United Kingdom. As of June 15, 2015, Prosonix Ltd. operates as a subsidiary of Circassia Limited.

Xceleron, founded in 1997 in York, UK, and now based in Germantown, Maryland, specializes in bioanalytical accelerator mass spectrometry (AMS) services to enhance drug development. The company pioneered techniques for human microdosing and microtracing, focusing on the pharmacokinetics and metabolism of developmental drugs during early clinical trial phases. Xceleron's services include micro-dosing, preclinical evaluation, intravenous pharmacokinetics, metabolite profiling, and mass balance investigations in humans. Their expertise is particularly valuable given the complexity of modern small molecules, which often exhibit low solubility and lengthy half-lives, necessitating early pharmacokinetic characterization to improve the cost-effectiveness of clinical development. Through a commitment to integrity and collaboration, Xceleron aims to accelerate the delivery of life-changing products to the market.

Prosonix Ltd. operates as a specialty pharmaceutical company, which develops and markets a portfolio of inhaled respiratory medicines to treat asthma and chronic obstructive pulmonary diseases. It develops generic mono and combination therapies based on inhaled corticosteroids (ICS), long-acting beta agonists (LABA), and long-acting muscarinic antagonists (LAMA); and dual and triple combination therapies for respiratory diseases based on its multiple-component particle technology. The company was founded in 2006 and is based in Oxford, United Kingdom. As of June 15, 2015, Prosonix Ltd. operates as a subsidiary of Circassia Limited.

Mobcast was founded in 2007 by CEO Tony Lynch and bestselling author Andy McNab. With the rise in the capabilities of mobile phones they spotted an opportunity to develop an online retail platform for digital books on these devices. They recognised the potential of gaining access to large customer bases and billing infrastructures through partnerships with mobile network operators, equipment manufacturers and retailers.

Concentra Consulting Limited specializes in advanced analytics services designed to enhance business performance across various sectors, including healthcare, pharmaceuticals, financial services, consumer goods, industrial, and automotive industries. Founded in 2005 and headquartered in London, with an additional office in Toronto, the company provides a range of services such as operations management, data visualization, and technology development. Its notable offerings include OrgVue, a solution for HR analytics and workforce planning; DataPlus, an automated software for data warehouse projects; and SupplyVue, which focuses on supply chain analytics. Concentra's commitment to integrating data science into management practices has earned it recognition in the industry, including awards for innovation in business analytics and human capital management.

Nimbus makes life at work easier, faster and more valuable for millions of people. Since its inception in 1997, Nimbus has helped over 700 organizations - including: Astrazeneca, Barclays Capital, HSBC, JPMorgan, RBS, Sara Lee, Toyota, and ThyssenKrupp.

Gaming Technology Solutions (GTS) is a global supplier of gaming solutions, established in 2005, specializing in delivering games through its EdGE platform. The company is licensed by the UK government as a software provider and caters exclusively to licensed gaming operators that accept bets from legal jurisdictions. GTS focuses on cross-channel gaming software for online gaming operations and has expanded its reach significantly since being acquired by Playtech in December 2009. Today, GTS provides open gaming services to over 90 internet operators worldwide, ensuring compliance with regulatory standards while enhancing the gaming experience for users.

Peakdale Molecular is a contract research organization. It provides drug discovery services to the pharmaceutical, biotech, diagnostics, and materials sciences industries. They operate a comprehensive suite of services for hit-to-lead and lead optimization studies, including early stage ADME. It offers a variety of customized commercial frameworks, from simple fee-for-service to long-term FTE projects. The company provides services such as drug discovery support, nucleoside chemistry, materials chemistry, research support, and business models. Peakdale Molecular was founded in 1992 and is headquartered in High Peak, Derbyshire.

Novalia Limited, based in Cambridge, United Kingdom, specializes in creating paper-thin self-adhesive touch sensors using printed conductive ink and integrated silicon microcontroller modules. Founded in 2006, the company develops bespoke interactive solutions that bridge the gap between the digital and physical worlds, allowing surfaces to respond to touch. Their technology is designed for various sectors, including media, advertising, music, healthcare, and retail, enabling brands to engage effectively with their audiences. By combining conductive printing with capacitive touch, Novalia's innovative approach facilitates interactive campaigns that enhance customer experiences, connecting brands to their target demographics in novel ways.